#pharma-stocks
Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbook
Investor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electronics but finds many small-cap defence stocks "obnoxious." Pharma offers decent but unexciting prospects. Sabharwal is con…
IT selloff drags Nifty below 24,000; pharma stocks buck the trend
Pharma bucked the broader trend and remained the standout performer of the session. Cipla led gains on the Nifty 50, rising 2.56 per cent to ₹1,452 with over 37.20 lakh shares traded worth ₹53,831.39 lakh
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?
Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remain…
Up to 531% returns: 23 small & midcap multibaggers you might have missed in 2026
Several small and midcap stocks have achieved multibagger status in 2026, offering substantial returns. Companies in sectors like fiber optics, defence, pharma, and solar energy have seen significant growth. This rally highlights thematic strengths overriding…
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pharma index rebounded from early losses to rise nearly 1%, crossing the 25,000 mark and hitting a fresh 52-week high of 25…
Pharma seen as safe bet amid currency volatility, says Ambareesh Baliga
Market veteran Ambareesh Baliga suggests pharmaceutical stocks offer a safe haven amidst currency volatility and cautious foreign investor sentiment. He advises focusing on top-tier pharma companies. Baliga also expresses caution on jewellery stocks due to in…
Earnings season is strong, but Q1 pain is coming: Dipan Mehta
Market expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to potential Iran-US war impacts. Mehta favors pharma stocks for their growth potential and attractive valuations. Specialty ch…